药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201231819040216.PDF,20082705091114.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文Chantix处方资料(仅供参考)
辉瑞推出戒烟新药Chantix 美国食品和药品管理局(FDA)批准了戒烟新药Chantix。据了解,该药为片剂,活性成分为varenicline tartrate,是一种新分子实体。由于该药将可为公众健康带来较大的益处,因此获得了FDA的优先审批权。据悉,Chantix作用于人体脑部受尼古丁影响的部位,通过两种方式帮助吸烟人士戒烟,可在一定程度上发挥与尼古丁相似的作用以缓解在戒烟过程中出现的戒断症状,并且在戒烟者戒烟后复吸时阻断烟草所含尼古丁对人体的作用。Chantix的戒烟效果在6个临床试验中得到了证实,与安慰剂对照组相比,该药的戒烟效果更佳。Chantix的疗程为12周,戒烟成功后,还需继续用药12周以保证长期的戒烟效果。其副作用包括恶心呕吐、头痛、肠胃气胀、失眠多梦和味觉减退。
辉瑞戒烟药物Chantix在美获批 辉瑞公司宣布,美国食品与药品管理局(FDA)批准了该公司戒烟药物Chantix的上市申请。这是迄今获得FDA批准的第二种不含尼古丁替代物的戒烟药。 Chantix是一种非尼古丁产品,可选择性作用于脑中的α4-β2尼古丁受体。这种药物不仅可以帮助吸烟者减轻戒烟症状,还可以阻断尼古丁对大脑产生的快感,从而防止戒烟者出现反复。据去年11月公布的临床试验结果显示,患者运用该药物治疗后第一年的戒烟率达到22%。
戒烟新药Chantix可降低尼古丁欣愉感 据路透社报道,美国洛杉矶一家临床研究机构的研究人员日前表示,他们发现新型戒烟药Chantix有助于降低对尼古丁的依赖。这种药已经得到美国药监局(FDA)批准。 研究人员称,Chantix可以关闭人体内尼古丁受体,后者会在吸烟者吞云吐雾的时候带给他们欣愉感觉。研究人员表示,这种新药可以降低吸烟者对尼古丁的依赖,并防止他们在戒烟后旧习难改。 研究人员在测试中随机挑选了626名志愿者,服药8个星期。第一个星期里,这626名志愿者就都戒除了烟瘾,在12个星期时,戒烟率仍然高达38.8%,到第52个星期时,戒烟率是14.4%。而对照组戒烟率分别是10.6%和4.9%。 研究人员还称,服用Chantix者对尼古丁依赖在任何时段都要比对照人员低很多。
Important Safety Information Some people have had changes in behavior, hostility, agitation, depressed mood, suicidal thoughts or actions while using CHANTIX to help them quit smoking. Some people had these symptoms when they began taking CHANTIX, and others developed them after several weeks of treatment or after stopping CHANTIX. If you, your family, or caregiver notice agitation, hostility, depression, or changes in behavior, thinking, or mood that are not typical for you, or you develop suicidal thoughts or actions, anxiety, panic, aggression, anger, mania, abnormal sensations, hallucinations, paranoia, or confusion, stop taking CHANTIX and call your doctor right away. Also tell your doctor about any history of depression or other mental health problems before taking CHANTIX, as these symptoms may worsen while taking CHANTIX.
Do not take CHANTIX if you have had a serious allergic or skin reaction to CHANTIX. Some people can have serious skin reactions while taking CHANTIX, some of which can become life-threatening. These can include rash, swelling, redness, and peeling of the skin. Some people can have allergic reactions to CHANTIX, some of which can be life-threatening and include: swelling of the face, mouth, and throat that can cause trouble breathing. If you have these symptoms or have a rash with peeling skin or blisters in your mouth, stop taking CHANTIX and get medical attention right away.
Tell your doctor if you have a history of heart or blood vessel problems before starting CHANTIX, or if you have a history of these problems and have any new or worse symptoms during treatment with CHANTIX. Get emergency medical help right away if you have any symptoms of a heart attack.
The most common side effects of CHANTIX include nausea (30%), sleep problems, constipation, gas and/or vomiting. If you have side effects that bother you or don't go away, tell your doctor. You may have trouble sleeping, vivid, unusual or strange dreams while taking CHANTIX. Use caution driving or operating machinery until you know how CHANTIX may affect you.
CHANTIX should not be taken with other quit-smoking products. You may need a lower dose of CHANTIX if you have kidney problems or get dialysis.
Before starting CHANTIX, tell your doctor if you are pregnant, plan to become pregnant, or if you take insulin, asthma medicines, or blood thinners. Medicines like these may work differently when you quit smoking.
What is CHANTIX CHANTIX is a prescription medicine that, along with support, helps adults 18 and over stop smoking. You may benefit from quit-smoking support programs and/or counseling during your quit attempt. It's possible that you might slip up and smoke while taking CHANTIX. If you do, you can stay on CHANTIX and keep trying to quit.
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201231819040216.PDF,20082705091114.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |